ACUITY(R) Spiral lead has smallest left ventricular lead tip profile in the
NATICK, Mass., May 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ACUITY(R) Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators (CRT-D) and cardiac resynchronization therapy pacemakers (CRT-P), both of which treat heart failure. The ACUITY Spiral lead is the Company's fifth generation left ventricular lead and second in the ACUITY family of left ventricular leads. The product features a spiral fixation design and small lead tip profile (4.1 French tapering to 2.6 French) for placement of the lead in veins of varying sizes, including difficult-to-access veins. A lead is an insulated wire that carries the heart signal to the implanted device and delivers energy from the device to the heart. In most cases, leads are passed into the heart through veins.
"In the U.S. clinical trial, the ACUITY Spiral fixation design provided excellent stability after implant," said John Hummel, M.D., principal investigator of the ACUITY Spiral U.S. clinical trial. "ACUITY Spiral has the smallest left ventricular lead tip profile in the industry, offering greater flexibility to place the lead in veins I may have avoided in the past."
Boston Scientific is also conducting a prospective, multi-center trial
designed to collect and analyze real-world performance data for the ACUITY
Spiral lead. The study will enroll approximately 1,700 patients in up to
125 centers. Patients will be followed over a period of five years and will
be enrolled on Boston Scientific's LATITUDE(R) Patient Management system
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved